Vesilute is a short peptide bioregulator developed within the Khavinson-school tradition of low-molecular-weight peptide research. It is classified as a tissue-specific bioregulator with reported affinity for urinary tract and bladder epithelial research models. Vesilute is part of a broader family of short peptides studied for their influence on tissue-specific gene expression in laboratory settings.
At the molecular level, Vesilute is investigated for its proposed role as a transcriptional modulator. Short peptide bioregulators of this class are studied for their ability to interact with promoter regions of DNA and influence the expression of genes involved in cellular turnover, differentiation, and tissue homeostasis. In urinary epithelial research models, Vesilute is examined for its influence on markers of epithelial renewal and stress adaptation under controlled in vitro conditions.
Vesilute is studied within research programs focused on tissue-renewal biology, urinary epithelial physiology, and age-associated changes in genitourinary tract research models. Khavinson-school investigations have characterized this and related short-peptide bioregulators as research tools for studying tissue-specific gene-expression patterns and cellular-turnover dynamics (Khavinson and Anisimov, 2009, Advances in Gerontology). Research interest continues in comparative studies that examine bioregulator peptides across multiple tissue-research contexts.
The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.
See also: Prostamax 20 mg, Cartalax 20 mg, and Crystagen 20 mg.
Specifications
- Purity: 99%
- Quantity: 20 mg
- Molecular Formula: C₉H₁₄N₂O₇
- Molecular Weight: 262.22 g/mol
Reviews
There are no reviews yet.